Posted by Michael Wonder on 02 Jan 2019

Schedule of Pharmaceutical Benefits - 1 January 2019 update

PBAC

1 January 2019 - The January 2019 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The January issue of the Schedule includes a number of new/revised listings:

  • Cetuximab (Erbitux) - new indication
  • Cladribine (Mavenclad) - new indication
  • Crizotinib (Xalkori) - new indication
  • Everolimus (Afinitor) - new indication
  • Somatropin (SciTropin A) - new strength
  • Tolvaptan (Jinarc) - new medicine

Read PBS Summary of Changes

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , Listing , Australia , Market access